Status:
COMPLETED
Cysteamine Compared to Hydroquinone in Melasma
Lead Sponsor:
China Medical University Hospital
Conditions:
Melasma
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
Melasma is an acquired pigmentary disorder of symmetrical hyperpigmentation appearing as variable darkness macules and patches over the forehead, cheeks, and chin, even sun-exposed areas of the body. ...
Eligibility Criteria
Inclusion
- a history of epidermal type melasma as diagnosed by a board-certified dermatologist
- above the age of 20 years
- Fitzpatrick skin type II-V
Exclusion
- pregnant
- breastfeeding
- currently receiving oral contraceptive pill or hormonal therapy
- have received topical hydroquinone, retinoid, tranexamic acid, or steroid treatment within the past month
- have received laser therapy or any other phototherapy within the past three months
- a history of allergic reactions to hydroquinone or cysteamine
- other pigmentary disorders of the face
- systemic diseases that may affect pigmentation of the face (such as systemic lupus erythematosus, jaundice, end-stage renal disease)
Key Trial Info
Start Date :
November 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2020
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT05969587
Start Date
November 28 2019
End Date
November 11 2020
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 404332